Brexucabtagene-autoleucel/dasatinib: Cytokine release syndrome, immune effector cell associated neurotoxicity syndrome and lack of efficacy.

A man in his 40s with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) experienced lack of efficacy with dasatinib treatment. He then received brexucabtagene-autoleucel and developed cytokine release syndrome and immune effector cell associated neurotoxicity syndrome, which resolved. The patient later showed improvement in ALL and underwent a second allogeneic hematopoietic stem-cell transplantation. [Extracted from the article]